Slingshot Insights

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CGEN

Community voting in process

Additional Information

Additional Relevant Details Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program

http://www.cgen.com/...

Management Comment Anat Cohen-Dayag, Ph.D., Compugen’s President and Chief Executive Officer stated, “We are pleased to present today these important results for therapeutic antibodies in our lead internal program CGEN-15029, a novel immune checkpoint target candidate for the treatment of cancer. Our identification of a binding partner during CGEN-15029’s target validation efforts has provided a much clearer path towards discovery and development of therapeutic antibodies against the target. Accordingly, we have successfully progressed through antibody discovery and identified antibodies that meet our key selection criteria for therapeutic candidates. We are now at the stage of selecting the therapeutic clinical candidate which we plan to advance to IND enabling studies, and are finalizing work plans for such advancement on various fronts, including manufacturing, preclinical and regulatory. We consider CGEN-15029 to be a very promising therapeutic and commercial opportunity, and look forward to disclosing further information regarding the program in the coming months.

http://www.cgen.com/...

Catalyst

Do you think this event is important to the companies below? How will it affect their stock price?

Additional Information

Slingshot Insights Explained